Search Results
Search for other papers by Tristan Avril in
Google Scholar
PubMed
Search for other papers by Quentin Hennocq in
Google Scholar
PubMed
Search for other papers by Anne-Sophie Lambert in
Google Scholar
PubMed
Université Paris Cité, Faculté de Santé, UFR de Médecine, Paris, France
Search for other papers by Juliane Leger in
Google Scholar
PubMed
Search for other papers by Dominique Simon in
Google Scholar
PubMed
Université Paris Cité, Faculté de Santé, UFR de Médecine, Paris, France
Inserm UMR1185, Le Kremlin Bicetre, Paris, France
Search for other papers by Laetitia Martinerie in
Google Scholar
PubMed
Inserm UMR1185, Le Kremlin Bicetre, Paris, France
Paris-Saclay University, Paris, France
Search for other papers by Claire Bouvattier in
Google Scholar
PubMed
Introduction Congenital hypogonadotropic hypogonadism (CHH), a rare genetic condition of unknown prevalence (approximately 1/5000), can be diagnosed shortly after birth in boys who present with micropenis and/or unilateral or bilateral
Search for other papers by Silvia Ciancia in
Google Scholar
PubMed
Search for other papers by Vanessa Dubois in
Google Scholar
PubMed
Search for other papers by Martine Cools in
Google Scholar
PubMed
). Even lower BMD values were observed in males with congenital hypogonadotropic hypogonadism ( 28 ). A reduced peak bone mass was also reported in females with delayed puberty and amenorrhea ( 29 , 30 ). The importance of appropriate timing of puberty
Search for other papers by Pamela Stratton in
Google Scholar
PubMed
Search for other papers by Neelam Giri in
Google Scholar
PubMed
Search for other papers by Sonia Bhala in
Google Scholar
PubMed
Search for other papers by Martha M Sklavos in
Google Scholar
PubMed
Search for other papers by Blanche P Alter in
Google Scholar
PubMed
Search for other papers by Sharon A Savage in
Google Scholar
PubMed
Search for other papers by Ligia A Pinto in
Google Scholar
PubMed
, and constitutive pubertal delay from congenital hypogonadotropic hypogonadism in prepubertal males ( 19 ). Additionally, AMH levels may be useful for assessing testicular damage across the lifespan, pre- and post-chemotherapy interventions, as a
Search for other papers by Milou Cecilia Madsen in
Google Scholar
PubMed
Search for other papers by Martin den Heijer in
Google Scholar
PubMed
Search for other papers by Claudia Pees in
Google Scholar
PubMed
Search for other papers by Nienke R Biermasz in
Google Scholar
PubMed
Search for other papers by Leontine E H Bakker in
Google Scholar
PubMed
Testosterone esters (TE) (Sustanon 250 mg every 3 weeks)/none 39 men with congenital hypogonadotropic hypogonadism vs 40 age-matched eugonadal men 6 months Improvement of sexual function Significant increase in BMI Benito 2005 (84